Glucocorticoid-induced osteoporosis in men

Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians

(2013) Amir Qaseem et al.   ANNALS OF INTERNAL MEDICINE

Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

(2011) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Update in Male Osteoporosis

(2010) Sundeep Khosla   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know

(2010) A. Catharine Ross et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Increased Fracture Risk in Patients with Rheumatic Disorders and Other Inflammatory Diseases -- A Case-Control Study with 53,108 Patients with Fracture

(2010) R. J. WEISS et al.   JOURNAL OF RHEUMATOLOGY

Osteoporosis in men: the value of laboratory testing

(2010) C. S. Ryan et al.   OSTEOPOROSIS INTERNATIONAL

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

(2010) Jennifer M. Grossman et al.   ARTHRITIS CARE & RESEARCH

Osteoporosis in Men: What has Changed?

(2010) Robert A. Adler   Current Osteoporosis Reports

Screening for Osteoporosis in the Adult U.S. Population

(2009) Lionel S. Lim et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

(2009) R. K. Dore et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial

(2009) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

(2009) David M Reid et al.   LANCET

Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

(2009) J. Compston et al.   MATURITAS

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

(2009) Matthew R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effects of a FRAX® revision for the USA

(2009) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL

Male risk factors for hip fracture—a 30-year follow-up study in 7,495 men

(2009) P. Trimpou et al.   OSTEOPOROSIS INTERNATIONAL

Prognosis of fracture: evaluation of predictive accuracy of the FRAX™ algorithm and Garvan nomogram

(2009) S. K. Sandhu et al.   OSTEOPOROSIS INTERNATIONAL

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Official Positions of the International Society for Clinical Densitometry and Executive Summary of the 2007 ISCD Position Development Conference

(2008) Sanford Baim et al.   JOURNAL OF CLINICAL DENSITOMETRY

Osteoporosis in Men

(2008) Peter R. Ebeling   NEW ENGLAND JOURNAL OF MEDICINE